LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

Search

Hutchison China MediTech Ltd ADR

Chiusa

SettoreSettore sanitario

15.99 -0.44

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

15.82

Massimo

16.05

Metriche Chiave

By Trading Economics

Entrata

6M

Vendite

162M

P/E

Media del settore

5.664

35.733

EPS

0.52

Margine di Profitto

3.676

Dipendenti

1,780

EBITDA

-5M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+56.54% upside

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

2.6B

Apertura precedente

16.43

Chiusura precedente

15.99

Punteggio Tecnico

By Trading Central

Fiducia

Strong Bearish Evidence

Hutchison China MediTech Ltd ADR Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

8 set 2025, 23:59 UTC

Acquisizioni, Fusioni, Takeovers

Anglo American Is in Talks to Buy Teck Resources, Bloomberg Says

8 set 2025, 22:02 UTC

I principali Market Mover

Microsoft Signs $17.4 Billion AI Deal With Nebius

8 set 2025, 17:01 UTC

I principali Market Mover

Eightco Holdings Stock Surges as Dan Ives Joins Board Amid Crypto Push

8 set 2025, 17:01 UTC

I principali Market Mover

Tron Shares Rise After New Investment From Bravemorning

8 set 2025, 16:14 UTC

I principali Market Mover

Beyond Air Shares Climb on FDA Orphan Drug Designation for Brain Cancer Treatment

8 set 2025, 16:13 UTC

I principali Market Mover

Dianthus Shares Whipsaw on Strong Trial Results, Safety Concerns

8 set 2025, 23:12 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

8 set 2025, 23:12 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

8 set 2025, 23:12 UTC

Discorsi di Mercato

Infratil's New Bull Likes Exposure to Growing Infrastructure Businesses -- Market Talk

8 set 2025, 22:56 UTC

Discorsi di Mercato

Worst May Be Over for New Zealand Retailers -- Market Talk

8 set 2025, 22:23 UTC

Discorsi di Mercato

Ebos's Near-Term Earnings Outlook Dims -- Market Talk

8 set 2025, 21:51 UTC

Discorsi di Mercato

AT&T Backs Outlook After EchoStar Spectrum Purchase -- Market Talk

8 set 2025, 21:47 UTC

I principali Market Mover

Microsoft Signs $17.4B AI Deal With Nebius

8 set 2025, 21:33 UTC

Acquisizioni, Fusioni, Takeovers

This Quantum Pure Play Is Going Public. What Infleqtion Does Differently, Says Its CEO. -- Barrons.com

8 set 2025, 21:20 UTC

Acquisizioni, Fusioni, Takeovers

MEG Energy Plans to Respond on or Before Sept 15 >MEG.T

8 set 2025, 21:19 UTC

Acquisizioni, Fusioni, Takeovers

MEG Energy Special Committee and Board Will Evaluate Revised Strathcona Offer >MEG.T

8 set 2025, 21:18 UTC

Acquisizioni, Fusioni, Takeovers

MEG Energy Acknowledges Strathcona's Intention to Revise Offer

8 set 2025, 20:50 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Tech, Media & Telecom Roundup: Market Talk

8 set 2025, 19:33 UTC

Discorsi di Mercato

Oil Futures Gain Despite Planned OPEC+ Output Increases -- Market Talk

8 set 2025, 19:22 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Settle Higher -- Market Talk

8 set 2025, 19:02 UTC

Discorsi di Mercato

Dollar Lukewarm Amid Data Hiatus Ahead of August CPI -- Market Talk

8 set 2025, 18:24 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

8 set 2025, 18:24 UTC

Discorsi di Mercato

Weaker Argentine Peso Profitable for Grain Producers -- Market Talk

8 set 2025, 17:29 UTC

Discorsi di Mercato

Mexican Inflation Seen Little Changed in August -- Market Talk

8 set 2025, 16:59 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

SpaceX Spectrum Acquisition Will Create More Satellite Connection Supply, Verizon CEO Says -- Market Talk

8 set 2025, 16:36 UTC

Discorsi di Mercato

Crude Futures Hold Gains After OPEC+ Output Decision -- Market Talk

8 set 2025, 16:20 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

8 set 2025, 16:16 UTC

Utili

Strategy Stock May Not Ever Make It Into the S&P 500 Index -- Barrons.com

8 set 2025, 16:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

8 set 2025, 16:04 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

Confronto tra pari

Modifica del prezzo

Hutchison China MediTech Ltd ADR Previsione

Obiettivo di Prezzo

By TipRanks

56.54% in crescita

Previsioni per 12 mesi

Media 25 USD  56.54%

Alto 25 USD

Basso 25 USD

Basato su 1 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Hutchison China MediTech Ltd ADR - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

1 ratings

1

Acquista

0

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

14.24 / 14.78Supporto e resistenza

A breve termine

Strong Bearish Evidence

A termine intermedio

Weak Bearish Evidence

A lungo termine

Weak Bearish Evidence

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.
help-icon Live chat